Collectively, targeted therapy in breast cancer illustrates how precise molecular subtyping can be translated into effective HER2-directed and pathway-focused regimens, while also revealing persistent obstacles such as primary and acquired resistance, treatment-related toxicity, and economic burden. This evidence concerns the gene ERBB2 and breast carcinoma.